Skip to main content
. 2018 Oct 9;12:3369–3375. doi: 10.2147/DDDT.S179427

Figure 4.

Figure 4

Nintedanib continuable curves of Mild to Moderate and Severe patients.

Note: A log-rank test revealed that there was significant difference in the continuation rate between two groups (P = 0.012).